← Leaderboards
Jennifer L Taylor-Cousar
Duke University
$1,736,834
Attributed
$6,177,598
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,177,598 · 8
By mechanism
UH3$3,477,195 · 1
UG3$1,851,722 · 1
K23$721,559 · 1
F32$67,049 · 1
M01$60,073 · 4
Top collaborators
- Daniel J Buysse4 shared
- Julio Fernandez-Mendoza4 shared
- Charles M. Morin4 shared
- Elizabeth Devon Smith4 shared
- Alexandros N Vgontzas4 shared
Most similar at Duke University
Same institution · by research overlap
- Jack D Edinger$11,027,957
- Annie Ouellet$979,125
- Dennis Alan Turner$11,694,617
- Charles Muiruri$735,851
- Tong H Lee$2,932,499
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsFundingResearch PersonnelMediatingFunctional DisorderPhysiologicalInstitutionCystic FibrosisUnited States National Institutes Of HealthCollaborationsClinical TrialsSymptomsNew MexicoInfectionUniversitiesClinical ResearchCystic Fibrosis PatientsResponseSafetyLaboratoriesLung DiseasesSildenafilExerciseInflammation
Grant awards (15)
1/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$1,467,809
UH3 · FY2025 · HL
1/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$262,705
UH3 · FY2025 · HL
1/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$1,746,681
UH3 · FY2024 · HL
1/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$1,851,722
UG3 · FY2023 · HL
Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF$120,732
K23 · FY2015 · HL · contact PI
Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF$151,048
K23 · FY2014 · HL · contact PI
Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF$151,340
K23 · FY2013 · HL · contact PI
Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF$151,667
K23 · FY2012 · HL · contact PI
Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF$146,772
K23 · FY2011 · HL · contact PI
THE ROLE OF SILDENAFIL IN MODERATE TO SEVERE CF LUNG DISEASE$4,333
M01 · FY2010 · RR · contact PI
A DOUBLE-BLIND, RANDOMIZED, MULTI-CENTER, PLACEBO-CONTROLLED,$44,731
M01 · FY2009 · RR · contact PI
MULTIDOSE SAFETY AND TOLERABILITY LIPOSOMAL AMIKACIN IN CYSTIC$6,193
M01 · FY2009 · RR · contact PI
THE ROLE OF SILDENAFIL IN MODERATE TO SEVERE CF LUNG DISEASE$4,816
M01 · FY2009 · RR · contact PI
Genetic Modifiers in CF: Role of ABH polymorphisms$5,178
F32 · FY2006 · HL · contact PI
Genetic Modifiers in CF: Role of ABH polymorphisms$61,871
F32 · FY2005 · HL